| Market Capitalization (Millions $) |
1,259 |
| Shares
Outstanding (Millions) |
50 |
| Employees |
215 |
| Revenues (TTM) (Millions $) |
100 |
| Net Income (TTM) (Millions $) |
-101 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Flexion Therapeutics Inc is a clinical stage biopharmaceutical company headquartered in Burlington, Massachusetts. It was founded in 2007 by Dr. Michael Clayman, an accomplished pharmaceutical executive, with a mission to develop differentiated, localized therapies for patients with musculoskeletal conditions. The company has a single focus on developing novel and innovative therapies for patients with osteoarthritis (OA), a degenerative joint disease that affects millions of people worldwide.
Flexion's lead product candidate is Zilretta, a sustained-release, intra-articular steroid injection for the treatment of OA-related knee pain. Zilretta's proprietary formulation of triamcinolone acetonide (TCA) is designed to provide prolonged pain relief for up to three months with a single injection. Flexion obtained FDA approval for Zilretta in October 2017, making it the first and only intra-articular extended-release steroid indicated for knee OA in the US.
Flexion is also developing FX201, a locally administered gene therapy candidate for the treatment of OA. FX201 is designed to inhibit the inflammatory cascade responsible for cartilage degradation by delivering a highly-specific RNA interference (RNAi) molecule to the affected joint. Clinical data from early-stage studies suggest that FX201 has the potential to be a highly-effective and safe treatment for OA.
In addition to its primary focus on OA, Flexion is also exploring opportunities to expand its pipeline into other musculoskeletal disorders, including back pain, joint pain, and tendinopathies. The company's advanced research capabilities and strong scientific expertise position it as a key player in the rapidly growing musculoskeletal market.
Flexion's management team is led by Dr. Michael Clayman, the company's founder and CEO, who brings extensive experience in the life sciences industry. The company's board of directors and scientific advisory board includes experts in the fields of medicine, biotechnology, and drug development, providing valuable guidance and support to the company's research efforts.
In summary, Flexion Therapeutics Inc is a biopharmaceutical company with a single focus on developing innovative therapies for patients with musculoskeletal disorders. Its lead product candidate, Zilretta, is the first and only intra-articular extended-release steroid approved by the FDA for the treatment of knee OA. The company's pipeline includes promising candidates such as FX201, a locally administered gene therapy for OA. Flexion's strong research capabilities, management team, and scientific advisory board make it a key player in the musculoskeletal market.
Company Address: 10 Mall Road Burlington 1803 MA
Company Phone Number: 305-7777 Stock Exchange / Ticker: NASDAQ FLXN
|
